Aethlon Medical (NASDAQ:AEMD) Share Price Passes Below 200-Day Moving Average – Here’s Why

Aethlon Medical, Inc. (NASDAQ:AEMD) shares crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.99 and traded as low as $0.59. Aethlon Medical shares last traded at $0.6005, with a volume of 44,648 shares changing hands.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aethlon Medical in a research report on Friday, July 17th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Aethlon Medical has a consensus rating of “Reduce”.

Aethlon Medical Stock Performance

The stock has a 50 day moving average price of $1.46 and a 200 day moving average price of $1.98. The company has a market cap of $1.39 million, a P/E ratio of -0.04 and a beta of 1.41.

Institutional Investors Weigh In On Aethlon Medical

An institutional investor recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC purchased a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical at the end of the most recent quarter. Hedge funds and other institutional investors own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical?stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life?threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.